register

News & Trends - Biotechnology

$10M investment fuels new biotech launch to target inflammatory lung disease

Health Industry Hub | May 9, 2022 |
[Total: 1    Average: 4/5]

Biotech News: An Australian biotech company has launched with AU$10 million seed investment to develop new therapies which target inflammatory diseases, particularly those affecting the lung.

Ankere Therapeutics aims to develop new therapies for inflammatory lung disease, based on its proprietary small molecule chemistry. Ankere is harnessing research from a collaboration between Associate Professor Bernard Flynn of Monash University’s Institute of Pharmaceutical Sciences and Professor Stuart Pitson of University of South Australia’s Centre for Cancer Biology, and has operations in both Melbourne and Adelaide.

Prof Pitson, a world leader in inflammatory cell signalling and Chief Scientific Officer at Ankere said “Ankere is an example of how a strong partnership between researchers with a shared area of focus has the potential to address the most pressing health concerns.

“The combination of research, expertise and capital at Ankere, will support the project to advance its highly promising discovery which has the potential to lead to new therapies targeting inflammation.”

Ankere’s CEO and Research Director, A/Prof Flynn, said “We are excited to be developing disease modifying therapies that have the potential to have a real global impact.” 

Dr Melissa McBurnie, Partner at Brandon Capital and Ankere Director, said “We’re excited to co-lead on this investment with IP Group, we’re aligned with a strong focus on the life sciences and backing the best biomedical innovations.”

“Collaboration is at the heart of the Brandon BioCatalyst model, we know that new therapies require different expert collaborators along the development path from the lab all the way through to patients in the clinic.”

Dr Siro Perez, Head of Life Sciences at IP Group Australia and Ankere Director, said “Ankere demonstrates what is possible when researchers from leading research centres come together.

“We are delighted to be working with the Ankere team and Brandon Capital to support this breakthrough research that has the potential to improve the lives of millions of people with chronic inflammatory conditions around the world. We are looking forward to sharing Ankere’s progress as they advance towards the clinic.”

Ankere is an Arrernte (central Australian Indigenous) word meaning spinifex wax which is used in traditional medicines. The use of the name is acknowledgement of Ankere’s Australian heritage and passion for better health outcomes. A/Prof Flynn received permission to use this word from the Arrernte culture centre, Akeyulerre, in Alice Springs.


News & Trends - Medical Technology

Calls for independent review of private health insurance as profits sky rocket and consumers lose out

Health Industry Hub | May 27, 2022 |

MedTech News: The Consumers Health Forum is again calling for an independent review of private health insurance as the Australian […]

More


Social Responsibility

J&J Medtech, Pfizer and Baxter Healthcare take action to ‘make change’ this National Reconciliation Week

Health Industry Hub | May 27, 2022 |

On election night, Anthony Albanese opened his acceptance speech with a full commitment to the Uluru Statement From the Heart. […]

More


News & Trends - Medical Technology

Surgical procedures postponed amid shortage of medical imaging

Health Industry Hub | May 27, 2022 |

MedTech News: Queensland Health will reschedule some non-urgent elective procedures due to a critical world-wide shortage of contrast solutions required […]

More


News & Trends - Medical Technology

Elective surgery wait times ‘longer than they have ever been’ in private hospitals

Health Industry Hub | May 27, 2022 |

MedTech News: A sharp increase in ‘missing’ episodes of care in Australia’s private hospitals in the first quarter of 2022 […]

More


This content is copyright protected